Myfortic (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myfortic, is an immunosuppressant presented as an enteric‑coated oral tablet for oral use. It is used to prevent organ rejection in transplant recipients and may be employed off‑label for certain autoimmune kidney diseases. GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Myfortic is an immunosuppressant that acts on the adaptive immune response to reduce graft rejection and control autoimmune activity. Renal transplantation: prevents organ rejection in kidney transplant recipients. Heart transplantation: reduces the risk of heart graft rejection. Liver transplantation: helps maintain liver graft function by limiting rejection. Lupus nephritis (off‑label): may be used to control severe kidney involvement in systemic lupus erythematosus.

Adverse reactions may occur with Myfortic use.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Abdominal pain: cramping or discomfort. - Headache: transient head pain. - Tremor: mild shaking of hands. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Infections: increased susceptibility to bacterial, viral or fungal infections. - Leukopenia: significant reduction in white blood cells. - Malignancy: heightened risk of certain cancers with long‑term use. - Severe liver injury: jaundice, elevated liver enzymes, or hepatic failure.

Patients should be monitored closely for safety concerns while taking Myfortic. Monitor blood counts: regular CBC to detect leukopenia or anemia. Assess renal function: check serum creatinine and eGFR periodically. Avoid live vaccines: immunosuppression can increase vaccine‑related complications. Educate on infection risk: advise prompt reporting of fever or signs of infection. Store at room temperature: keep tablets in the original container, protect from moisture and heat.

Myfortic may interact with other medications, requiring careful management.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Cyclosporine or tacrolimus: increased nephrotoxicity. - Cholestyramine: reduces absorption of mycophenolic acid.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect. - Statins: potential for increased myopathy risk. - Live attenuated vaccines: may diminish vaccine efficacy and increase infection risk.